SavedAdd your journal

Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2014 / Cilt: 20 - Sayı: 6

Sıçanlarda bortezomib indüklü karaciğer hasarında B-1,3-(D)-glukan ın hepatoprotektif etkileri

Hüseyin Serkan EROL
Burak ERDEMCİ
Serpil CAN
Suat ÇOLAK
İsmail CAN
Bülent Çağlar BİLGİN
Nurhan AKARAS
Mesut Bünyamin HALICI
Gülşen ÇIĞŞAR
Bünyami ÜNAL
Osman Nuri KELEŞ
Pages
929–938
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Administration of β -1,3-(D)-Glucan isefective in reversing tissue damage induced by bortezomib in rat livers.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to evaluate the efects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and studythe biochemical, histopathologic, and immunohistochemical efects of first therapeutic proteasome inhibitor bortezomib on theliver for treating relapsed multiple myeloma.
📊
Key Findings & Data:The experiment included 36 adult male rats, which were divided into four treatmentgroups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated.
💡
Conclusion & Impact:Administration of β -1,3-(D)-Glucan isefective in reversing tissue damage induced by bortezomib in rat livers.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to evaluate the efects of β -1,3-(D)-glucan as an antioxidant and tissue protective agent and studythe biochemical, histopathologic, and immunohistochemical efects of first therapeutic proteasome inhibitor bortezomib on theliver for treating relapsed multiple myeloma. The experiment included 36 adult male rats, which were divided into four treatmentgroups: control (healthy); bortezomib-treated; β-1,3-D-glucan-treated; and bortezomib + β-1,3-(D)-glucan-treated. Each group wassubdivided into two subgroups based on time of sacrifice (48 or 72 h). After the experiments, superoxide dismutase (SOD) activityand lipid peroxidation (LPO) amounts were determined, and immunohistochemical and histopathological changes were examinedin all rat liver tissues. β -1,3-(D)-Glucan treatment normalized changes of LPO and stimulated an over activity of endogenous SOD.The results of the histopathologic parameters showed that treatment with β -1,3-(D)-Glucan in the bortezomib group amelioratedthe development of non-specific reactive hepatitis (NSRH) and Kupfer cell activation via NF-kB. Administration of β -1,3-(D)-Glucan isefective in reversing tissue damage induced by bortezomib in rat livers.

🔖

Cite This Article

EROL, H. S., ERDEMCİ, B., CAN, S., ÇOLAK, S., CAN, İ., BİLGİN, B. Ç., AKARAS, N., HALICI, M. B., ÇIĞŞAR, G., ÜNAL, B., KELEŞ, O. N. (2022). Sıçanlarda bortezomib indüklü karaciğer hasarında B-1,3-(D)-glukan ın hepatoprotektif etkileri. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 20 - Sayı: 6, 929–938. https://ajindex.com/articles/569931

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Demasi M, Netto LE, Silva GM, Hand A, de Oliveira CL, Bicev RN, Gozzo F, Barros MH, Leme JM, Ohara E: Redox regulation of the proteasome via S-glutathionylation. Redox Biol, 14 (2): 44-51, 2013
  2. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013
  3. Yerlikaya A, Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med, 22 (6): 817-823, 2008
  4. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S: Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer, 7 (40): 1-14, 2008
  5. Voorhees PM, Dees EC, O’Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res, 9 (17): 6316-6325, 2003
  6. Elliott PJ, Zollner TM, Boehncke WH: Proteasome inhibition: A new anti-infammatory strategy. J Mol Med (Berl), 81(4): 235-245, 2003
  7. James SE, Dunham M, Carrion-Jones M, Murashov A, Lu Q: Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology, 31 (2): 188-194, 2010
  8. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: Identification of circulating metabolites. Drug Metab Dispos, 33 (6): 771-777, 2005
  9. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, Takayama H, Kikuchi A, Kanamori T, Shima KR, Lan F, Takeda T, Kurita S, Ishikura K, Kita Y, Iwayama K, Kato K, Uno M, Takeshita Y, Yamamoto M, Tokuyama K, Iseki S, Tanaka K, Kaneko S: Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes, 62 (3): 811-824, 2013
  10. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos, 34 (4): 702-708, 2006
  11. Amin A, Hamza AA: Oxidative stress mediates drug-induced hepatotoxicity in rats: A possible role of DNA fragmentation. Toxicology, 208 (3): 367-375, 2005
  12. Block KI, Koch AC, Me